- Home
- LNTH vs NCLH Comparison
LNTH vs NCLH Comparison
Compare LNTH & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNTH | NCLH |
|---|---|---|
| Founded | 1956 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 10.7B |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LNTH | NCLH |
|---|---|---|
| Price | $66.42 | $22.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 18 |
| Target Price | ★ $78.00 | $28.11 |
| AVG Volume (30 Days) | 1.2M | ★ 17.1M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.76 |
| EPS | ★ 2.39 | 1.40 |
| Revenue | $1,525,933,000.00 | ★ $9,692,558,000.00 |
| Revenue This Year | $0.01 | $6.85 |
| Revenue Next Year | $0.52 | $10.76 |
| P/E Ratio | $27.87 | ★ $16.58 |
| Revenue Growth | 1.95 | ★ 3.59 |
| 52 Week Low | $47.25 | $14.21 |
| 52 Week High | $111.29 | $29.29 |
Technical Indicators
Market Signals| Indicator | LNTH | NCLH |
|---|---|---|
| Relative Strength Index (RSI) | 65.52 | 64.62 |
| Support Level | $64.13 | $21.51 |
| Resistance Level | $68.84 | $24.32 |
| Average True Range (ATR) | 1.90 | 0.84 |
| MACD | 0.10 | 0.39 |
| Stochastic Oscillator | 75.47 | 75.30 |
Price Performance
Historical ComparisonAbout LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.